The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Real-world (rw) treatment (tx) patterns and overall survival (OS) in patients (pts) with locally advanced/metastatic urothelial carcinoma (la/mUC) treated with avelumab first-line maintenance (1LM): Updated results from the SPEAR Bladder II study.
 
manojkumar bupathi
Honoraria - Agendia; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb; Exelixis; Exelixis; Exelixis; Exelixis; Janssen; Myovant Sciences; Pfizer
Consulting or Advisory Role - AstraZeneca; AstraZeneca; Bristol-Myers Squibb; Exelixis
Speakers' Bureau - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Exelixis; Janssen Oncology; Pfizer
 
Sneha Sura
Employment - Ontada/McKesson
 
Chiemeka Ike
Employment - EMD Serono
Stock and Other Ownership Interests - Merck
 
Valerie A. Morris
Employment - EMD Serono
Stock and Other Ownership Interests - Merck
 
Paul R. Conkling
Employment - Ontada/McKesson; Virginia Oncology Associates
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo/Lilly; EMD Serono (Inst); Janssen (Inst)
 
Karen Todoroff
Employment - Ontada/McKesson
 
Abhijeet Bhanegaonkar
Employment - EMD Serono